Find Clinical Trials | Cedars-Sinai

396 results found

Melanoma

PF-07799544 as a Single Agent and in Combination With Other Targeted Agents in BRAF-Mutant Melanoma and Other Solid Tumors

This study focuses on people who have melanoma (skin cancer) or other cancer with a specific change in the BRAF gene (BRAF alteration) and whose cancer has grown or spread. The study will explore the ...

Other

BD BACTECTM FXI Culture System vs BD BACTECTM FX in the Detection of Bloodstream Infections

The purpose of this study is to collect blood cultures from individuals suspected of having a blood stream infection (BSI). A BSI is caused by bacteria or fungi in the blood stream that causes one ...

Movement Disorders

BIIB122 in Participants With LRRK2-Associated Parkinson's Disease

The purpose of this study is to evaluate whether an experimental drug called BIIB122 is safe and tolerable in LRRK2-associated Parkinson’s disease (LRRK2-PD) patients. LRRK2-PD is a form of Parkinson’s disease caused by genetic mutation(s) ...

Non-Hodgkin's Lymphoma, Other Hematopoietic

MK-2140 in Combination With R-CHP Versus R-CHOP in Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety and effectiveness of the combination of an experimental drug called zilovertamab vedotin (MK-2140) plus a series of cancer drugs (R-CHP) in treating people with diffuse ...

Melanoma

Regeneron, R3767-ONC-2466, Ph2, open label, Melanoma, Fianlimab Plus Cemiplimab

Primary -Assess Overall Survival (OS) of patients with melanoma treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613 Secondary -Assess Progression-Free Survival (PFS) -Assess Objective Response Rate (ORR) -Assess Duration of Response (DOR) -Assess Disease Control Rate (DCR) ...